Alector, Inc. (NASDAQ:ALEC) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Alector, Inc. (NASDAQ:ALEC) have been assigned an average rating of “Moderate Buy” from the seven brokerages that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have given a buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $14.86.

Separately, HC Wainwright reiterated a “buy” rating and issued a $41.00 price objective on shares of Alector in a report on Wednesday, February 28th.

Alector Price Performance

Shares of Alector stock opened at $5.30 on Wednesday. The firm has a market cap of $510.87 million, a price-to-earnings ratio of -3.42 and a beta of 0.82. The stock has a 50-day simple moving average of $5.90 and a 200-day simple moving average of $6.13. Alector has a 52-week low of $3.66 and a 52-week high of $9.06.

Alector (NASDAQ:ALEC) last posted its earnings results on Tuesday, February 27th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.31. The firm had revenue of $15.19 million during the quarter, compared to analysts’ expectations of $8.35 million. Alector had a negative net margin of 134.34% and a negative return on equity of 77.15%. As a group, equities research analysts predict that Alector will post -1.89 earnings per share for the current year.

Insider Transactions at Alector

In related news, CFO Marc Grasso sold 5,716 shares of the company’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $6.92, for a total transaction of $39,554.72. Following the completion of the sale, the chief financial officer now directly owns 144,957 shares of the company’s stock, valued at approximately $1,003,102.44. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other news, CFO Marc Grasso sold 5,716 shares of Alector stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $6.92, for a total value of $39,554.72. Following the transaction, the chief financial officer now directly owns 144,957 shares in the company, valued at $1,003,102.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Arnon Rosenthal sold 18,837 shares of the stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $6.92, for a total value of $130,352.04. Following the sale, the chief executive officer now owns 2,000,380 shares of the company’s stock, valued at approximately $13,842,629.60. The disclosure for this sale can be found here. Over the last three months, insiders sold 30,554 shares of company stock worth $211,434. 14.00% of the stock is owned by insiders.

Hedge Funds Weigh In On Alector

A number of institutional investors and hedge funds have recently bought and sold shares of ALEC. Diversified Trust Co increased its holdings in shares of Alector by 12.3% during the 4th quarter. Diversified Trust Co now owns 14,102 shares of the company’s stock worth $113,000 after purchasing an additional 1,541 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Alector by 3.6% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 61,239 shares of the company’s stock valued at $489,000 after buying an additional 2,120 shares during the period. Rafferty Asset Management LLC grew its position in Alector by 2.3% during the fourth quarter. Rafferty Asset Management LLC now owns 190,911 shares of the company’s stock worth $1,523,000 after buying an additional 4,287 shares in the last quarter. Blackstone Inc. increased its stake in Alector by 50.0% during the third quarter. Blackstone Inc. now owns 15,429 shares of the company’s stock valued at $100,000 after acquiring an additional 5,143 shares during the period. Finally, Allspring Global Investments Holdings LLC acquired a new position in Alector in the 1st quarter valued at approximately $40,000. Institutional investors own 85.83% of the company’s stock.

Alector Company Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.